Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17634052 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1TSHRMAPK1CASP7 | |
| SCHEMBL17638810 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1TSHRMAPK1CASP7 | |
| SCHEMBL17634041 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1TSHRMAPK1CASP7 | |
| SCHEMBL6830271 | 0.78 | — | — | |
| SCHEMBL24250131 | 0.76 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1TSHRMAPK1CASP7 | |
| SCHEMBL19300028 | 0.74 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL19300209 | 0.74 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL19300027 | 0.74 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL8223673 | 0.73 | CA1 (0.43) | SMN1; SMN2ALDH1A1CA14CA12CA1 | |
| SCHEMBL15041053 | 0.73 | CA1 (0.43) | SMN1; SMN2ALDH1A1CA14CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207153-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207153-A1 | UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | FPR1, FPR2, SAAL1 | SMN1; SMN2 623/4885ALDH1A1 2705/4885TSHR 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.